Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients. Data showed decreased glycolytic activity in red blood cells of 2/3 of patients with lower-risk MDS. These results highlight a potential effect of the PK activator in this setting.
Glycolytic activity and in vitro effect of the pyruvate kinase activator AG‐946 in red blood cells from low‐risk myelodysplastic syndromes patients: A proof‐of‐concept study / B. Fattizzo, C. Vercellati, A. Marcello, P. Patel, M. Wind‐rotolo, L. Pettine, M. Bonanomi, D. Gaglio, M. Bortolotti, C. Leoni, E. Fermo, P. Bianchi, A. Zaninoni, F. Passamonti, W. Barcellini. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 99:6(2024), pp. 1201-1204. [10.1002/ajh.27300]
Glycolytic activity and in vitro effect of the pyruvate kinase activator AG‐946 in red blood cells from low‐risk myelodysplastic syndromes patients: A proof‐of‐concept study
B. Fattizzo
Primo
;A. Marcello;L. Pettine;M. Bortolotti;C. Leoni;F. Passamonti;
2024
Abstract
Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients. Data showed decreased glycolytic activity in red blood cells of 2/3 of patients with lower-risk MDS. These results highlight a potential effect of the PK activator in this setting.
| File | Dimensione | Formato | |
|---|---|---|---|
|
American J Hematol - 2024 - Fattizzo - Glycolytic activity and in vitro effect of the pyruvate kinase activator AG‐946 in.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.5 MB
Formato
Adobe PDF
|
1.5 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
